DrugPatentWatch Database Preview

Taro Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for TARO PHARM, and what generic alternatives to TARO PHARM drugs are available?

TARO PHARM has thirty-nine approved drugs.

There are three US patents protecting TARO PHARM drugs. There are two tentative approvals on TARO PHARM drugs.

There are twenty-five patent family members on TARO PHARM drugs in thirteen countries and twenty-two supplementary protection certificates in nine countries.

Summary for Taro Pharm

International Patents:	25
US Patents:	3
Tradenames:	36
Ingredients:	33
NDAs:	39
Patent Litigation for Taro Pharm:	See patent lawsuits for Taro Pharm

Drugs and US Patents for Taro Pharm

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Taro Pharm	AMIODARONE HYDROCHLORIDE	amiodarone hydrochloride	TABLET;ORAL	075424-002	Dec 18, 2002	AB	RX	No	No
Taro Pharms North	PSORCON	diflorasone diacetate	CREAM;TOPICAL	020205-001	Nov 20, 1992		DISCN	Yes	No
Taro Pharm	CLORAZEPATE DIPOTASSIUM	clorazepate dipotassium	TABLET;ORAL	075731-001	Apr 27, 2000	AB	RX	No	No
Taro Pharm	AMIODARONE HYDROCHLORIDE	amiodarone hydrochloride	TABLET;ORAL	075424-001	Mar 30, 2001	AB	RX	No	No

Expired US Patents for Taro Pharm

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Taro Pharms	PLIAGLIS	lidocaine; tetracaine	CREAM;TOPICAL	021717-001	Jun 29, 2006	5,919,479

Paragraph IV (Patent) Challenges for TARO PHARM drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Topical Lotion	0.5%		2011-03-16

Non-Orange Book US Patents for Taro Pharm

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,957,238	Process for preparing malathion for pharmaceutical use
8,039,657	Process for preparing malathion for pharmaceutical use
8,536,155	Process for preparing malathion for pharmaceutical use

International Patents for Taro Pharm Drugs

Country	Document Number	Estimated Expiration
Brazil	PI0612686
Japan	5474347
Canada	2612578
Israel	188512

Supplementary Protection Certificates for Taro Pharm Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C0067	France		PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
2013025,C1304992	Lithuania		PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
C/GB08/005	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
01C/013	Belgium		PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Taro
• Taro Pharm
• Taro Pharm Inds
• Taro Pharms